Programs & products

IPH2201 is the third monoclonal antibody developed in collaboration with Novo Nordisk A/S expected to enter clinical trials Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) announces...

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) announces that the National Cancer Institute (“NCI”, National Institutes of Health, “NIH”, Bethesda, Maryland, USA) has enrolled a...

Innate Pharma announces today that it has started patient inclusion in a new multicenter Phase II clinical trial with IPH2101, an anti-KIR monoclonal antibody potentiating the anti-tumor activity of...

Favorable complete response rate with IPH 1101 associated with low-dose IL-2 in combination with rituximab Last trial of the clinical program for IPH 1101 completed in a context where new cancer...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today that it will report clinical data for its two lead clinical drug candidate at the following June’s medical meetings: EHA and ASCO At...

Updated Phase II interim results with IPH 1101 in non-Hodgkin’s lymphoma on a larger cohort confirming encouraging trend in complete response rate Update on IPH 2101 Phase I trials and new set of pre...

Initiation of a Phase II trial in multiple myeloma evaluating the combination of IPH 2101 - a fully human anti-KIR monoclonal antibody stimulating NK cells' anti-tumoral activity, with Celgene’s...

Encouraging interim efficacy data in non-Hodgkin’s lymphoma (“NHL”) reported at the ESMO meeting in Berlin; complete response rate above current standard of care for the first set of patients...

Over a three-year period, Inserm Transfert will make available to Innate Pharma information on early-stage antibody targets discovered within Inserm’s academic research laboratories, for the purpose...

Approval by the French regulatory authorities of a first Phase IIa clinical trial with IPH 2101 in patients suffering from Multiple Myeloma, a severe haematological cancer Conducted in France, this...